Tanvex Biopharma, Inc.TWSE: 6541

The Company has been required by TWSE to announce the financial data according to the regulations

· Issued by Tanvex BioPharma, Inc.
Close
Today's Information

Provided by: Tanvex BioPharma, Inc.
SEQ_NO 1 Date of announcement 2022/08/04 Time of announcement 16:05:00
Subject
 The Company has been required by TWSE to announce
the financial data according to the regulations
Date of events 2022/08/04 To which item it meets paragraph 51
Statement
1.Date of occurrence of the event:2022/08/04
2.Cause of occurrence:Request by TWSE to announce relevant information
3.Financial and business information:
Period             (Month)             (Quarter)        (Recent 4 quarter)
====    ==========  ==========  ======
Item         Previous month         Previous quarter      2021 Q2~
             June 2022                  2022 Q1             2022 Q1
             (Financial Statement
             -Unaudited) YoY %                  YoY %
====    ==== ===== ===== =====  ======
Revenue         1         0           3        0          8
(Million)
Net Profit
before tax   (130)    60.49%       (332)   (20.00%)     (1,460)
(Million)
Net profit   (130)    60.49%       (332)   (20.00%)     (1,460)
(Million)
EPS          (0.37)   41.85%       (0.94)  (20.00%)      (4.35)
(dollar)
4.Any matters regarding to "Taiwan stock exchange corporation procedure for
  verification and disclosure of material information of companies with
  listed securities" article 4 that need to be specified:None.
5.Any matters regarding to "Taiwan stock exchange corporation procedure for
  verification and disclosure of material information of companies with
  listed securities" article 11 that need to be specified:None.
6.Please inquiry the items of financial Information on the website of MOPS,
and the paths as follow:
(1)Current sales revenue/income(loss):
Summaries>Financial Information applicable after adopting IFRSs
(2)Historic sales revenue per month:
Operating Statements>Monthly Sales Revenue>
Statement of Sales Revenue(after adopting IFRSs)
(3)Historic income or loss(audited/reviewed by the CPA):
Financial Statements>
FINANCIAL STATEMENT after adopting IFRSs>Balance Sheet/Income Statement
(4)Historic income or loss (self-assessed):
Operating Statements>Self-assessed income or loss:
7.Any other matters that need to be specified:None.

Company analysis

Earlier from Tanvex Biopharma

All Tanvex Biopharma news releases